ArticleBMJ public health2024
Association between coexisting hypertension, dyslipidaemia and elevated C reactive protein with cardiovascular disease and mortality: a cross-sectional and longitudinal analysis in a representative cohort of older US adults.
Article in BMJ public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Global prevalence of nocturnal hypertension: systematic review and meta-analysis.BMC public health · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Objective: Hypertension and dyslipidemia are established risk factors for cardiovascular disease (CVD), but are often insufficient alone in predicting CVD. Inflammation also contributes to CVD, but research on the co-occurrence of inflammation, hypertension, and dyslipidemia and CVD risk is limited. Knowledge of inflammatory status in addition to other risk factors is vital for clinicians to correctly evaluate patients for CVD risk. Methods: Prospective data from the Health and Retirement Study, a representative cohort of US adults over 50 years of age (n = 7895) were used. The average participant age was 68.8 years, and 54.9% were female. 80.7% were Non-Hispanic White, 10.1% were Non-Hispanic Black, and 9.2% were Hispanic. Hypertension, dyslipidemia, and elevated C-reactive protein (CRP) were used to create a CVD risk score: low (0-1 factors), medium (2 factors), or high (all 3 factors). Measurement and definition guidelines for these variables are thoroughly explained in the methods section. Weighted logistic regression models estimated the odds ratio (OR) of 1) prevalent and incident CVD for medium and high-risk groups versus the low-risk group and 2) 4-year mortality adjusting for covariates. Results: Cross-sectionally, high-risk participants (n=1706) had significantly higher odds of CVD prevalence compared to participants with low-risk (n=3107) (adjusted OR = 1.54, 95% CI: [1.29 - 1.84]). Medium-risk (n=3082) participants had higher odds of CVD prevalence, though this did not reach significance. Prospectively, medium and high-risk participants had significantly higher odds of 4-year CVD incidence (medium-risk adjusted OR = 1.57, 95% CI: [1.18 - 2.09]; high-risk adjusted OR = 1.67, 95% CI: [1.19 - 2.36]) compared to those with low-risk. Risk of 4-year mortality was higher in high-risk (OR = 2.12, 95% CI: [1.60 - 2.8]) participants vs. low-risk, and non-significantly elevated in medium-risk participants. Conclusions: Co-occurrence of hypertension, dyslipidemia, and elevated CRP was strongly associated with increased CVD prevalence, higher incident CVD, and elevated 4-year mortality in older US adults, emphasizing the importance of multifactor screening for CVD risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.